Drugs / CDX-1135
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01791686 | Jan 2013 → Mar 2014 | C3 glomerulonephritis, dense deposit disease | Celldex Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CDX-1135 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01791686 ↗ |
| Known as | YM-203 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297720 ↗ |
| Route | Intravenous | “Patients will receive CDX-1135 as an IV infusion twice weekly” NCT01791686 ↗ |